Debt-to-equity of Cerevel Therapeutics Holdings, Inc. from 31 Mar 2021 to 31 Mar 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Cerevel Therapeutics Holdings, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2021 to 31 Mar 2024.
  • Cerevel Therapeutics Holdings, Inc. Debt-to-equity for the quarter ending 31 Mar 2024 was 120%, a 47% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Cerevel Therapeutics Holdings, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q1 2024 120% +38% +47% 31 Mar 2024
Q4 2023 125% +66% +114% 31 Dec 2023
Q3 2023 132% +93% +239% 30 Sep 2023
Q2 2023 106% +86% +410% 30 Jun 2023
Q1 2023 81% +61% +301% 31 Mar 2023
Q4 2022 58% +38% +184% 31 Dec 2022
Q3 2022 39% +19% +95% 30 Sep 2022
Q2 2022 21% -2.1% -9.2% 30 Jun 2022
Q1 2022 20% +0.65% +3.3% 31 Mar 2022
Q4 2021 21% 31 Dec 2021
Q3 2021 20% 30 Sep 2021
Q2 2021 23% 30 Jun 2021
Q1 2021 20% 31 Mar 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.